Cancer Trials Ireland > Cancer Trials > Lymphoma & blood cancers

DSSG Group: Lymphoma & blood cancers

Beigene 311-308 / MAHOGANY

Name No. For Patients with Purpose
Beigene 311-308 / MAHOGANY 24-30

Relapsed/Refractory Follicular or Marginal Zone Lymphoma
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Cell-free DNA

Name No. For Patients with Purpose
Cell-free DNA 24-29

High Grade non-Hodgkin’s lymphoma

BD CHaPTeR

Name No. For Patients with Purpose
BD CHaPTeR 24-26

Clinical Haematology Patients

BD – Bone Marrow/Blood

Name No. For Patients with Purpose
BD – Bone Marrow/Blood

Healthy Volunteers for Research and Development Purpose
Bone Marrow and Blood Sample  and Procurement from Healthy Volunteers for Research and Development Purpose

BCBI

Name No. For Patients with Purpose
BCBI 24-13

Blood Cancer

The BCNI biobank is called Blood Cancer Biobank Ireland (BCBI). It is a national effort coordinating and standardizing blood cancer biobanking activities at sites in Galway, Dublin, Cork, Limerick and Waterford.

firmMIND INCMOR0208-305

Name No. For Patients with Purpose
firmMIND INCMOR0208-305 24-05

Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).

LOXO-BTK-20022

Name No. For Patients with Purpose
LOXO-BTK-20022 21-44

Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

MRD Study

Name No. For Patients with Purpose
MRD Study 21-23

Patients with Myeloma.
Minimal residual disease (MRD). This is a test performed on the patients DNA at diagnosis by Next Generation Sequencing (NGS), which can detect if there are trace amounts of the cancer remaining in a patient after treatment, and has been shown to be highly predictive of long-term outcomes in several studies.

MK2140-006

Name No. For Patients with Purpose
MK2140-006 23-16

Selected Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter’s transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate.